Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(10%)
Results Posted
25%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
4
40%
Ph not_applicable
1
10%
Ph phase_3
1
10%
Ph phase_1
4
40%

Phase Distribution

4

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
1(10.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(4)
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Not yet recruiting3
Recruiting1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (40.0%)
Phase 24 (40.0%)
Phase 31 (10.0%)
N/A1 (10.0%)

Trials by Status

recruiting110%
terminated110%
unknown110%
completed440%
not_yet_recruiting330%

Recent Activity

1 active trials
Showing 5 of 10
completedphase_1

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

NCT05383352
completedphase_3

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

NCT03088813
completedphase_1

Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance

NCT04728035
terminatedphase_2

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

NCT05009953
completedphase_2

Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)

NCT04727853
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05383352Phase 1

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

Completed
NCT03088813Phase 3

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

Completed
NCT04728035Phase 1

Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance

Completed
NCT05009953Phase 2

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Terminated
NCT04727853Phase 2

Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)

Completed
NCT06370754Phase 1

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Not Yet Recruiting
NCT06361316Not Applicable

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Recruiting
NCT06259058Phase 1

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Not Yet Recruiting
NCT06210360Phase 2

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Not Yet Recruiting
NCT05047991Phase 2

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10